Cannabinoid Biosciences Inc. (CBDZ), a California biotechnology startup that seeks to revolutionize and standardize the pharmaceuticals and non-pharmaceutical CBD products across the CBD market in the United States of America and to some extent, globally, is pleased to announce the selection of KoreConX as our transfer agent.
We have partnered with KoreConX as our transfer agent, who provide an online platform to allow investors to manage their investment in our company. We will use the platform to send their reporting, news releases and it will give investors the ability transfers and trades. KoreConX is the first all-in-one platform for private companies to manage company records, capital market activity, fundraising and investments.
The United States Securities and Exchange Commission (SEC) had on April 16, 2019, qualified CBDZ Regulation A+ Offering Circular to raise $50 million from the public offering.
CBDZ management alongside its stock transfer agent, KoreConX, CBDZ is currently designing its customized platform for the onboarding of investors. Once the platform is ready, CBDZ will launch its crowdfunding campaign to raise the $50 million it has been qualified to raise by the SEC.
About Cannabinoid Biosciences Inc.
Meta description: Cannabinoid Biosciences, Inc., (“CBDZ”) is a biopharmaceutical company with interests in the discovery, development, and commercialization of medical cannabis products.
CBDZ’smission is to revolutionize and standardize the pharmaceuticals and non-pharmaceutical CBD products across the CBD market in the United States of America and to some extent, globally. CBDZ seeks to control the production and distribution of verities of consumer cannabidiol (CBD) formulation under private brands in the United States. CBDZ’s goal is to bring standardization to the CBD industry, the same way that John D Rockefeller’s Standard Oil brought standardization to crude refining in the United States in the nineteenth century. CBDZ’s product lineup includes tinctures, capsules, gummies, bath bombs, vape oils, topical creams, and animal treats and oils. The company will sell its products directly to consumers through the company Website, as well as non-affiliated stores in about 40 states. The company was founded in 2014 and is based in Los Angeles, California. https://cbdxfund.com/invest/
The global cannabis industry has been witnessing tremendous growth in recent years. In 2018 alone, global cannabis sales hit $12.2 billion, with an expectation of over 30% growth for 2019. The use of medical cannabis has been given the green light in 33 states while 10 states have also legalized its recreational use. The Californian cannabis industry alone is expected to be worth $6.6 billion by 2020. By the same year, the total US-based market might have as well increased to $23 billion — from just the $3.4 billion valuation in 2015.
However, there is a problem. For someone seeking a bargain, getting in on the ground floor of cannabis investment has become prohibitively expensive. This fact can be perfectly illustrated with the $1.8 billion deal whereby Altria, the Marlboro cigarette manufacturer, paid $250 per 1$ of Cronos’ revenue to acquire a 45% stake in the Canadian cannabis company which generated only $16 million in annual revenue in its most recent fiscal year. Also, the current average market capitalization to revenue of $131 per $1 for publicly traded cannabis businesses makes it almost impossible to find bargain deals in the cannabis investment space.
However, then enters CBDZ.
Cannabinoid Biosciences, Inc., (“CBDZ”), is a biopharmaceutical company founded in May 2014. The company is interested in the discovery, development, and commercialization of novel drugs using different cannabis products —proprietary cannabinoid, cannabidiol, endocannabinoids, phytocannabinoids, and synthetic cannabinoid products. Its operating strategy is research and development and pipeline acquisition.
Hence, the aim of the company, using this approach, is to develop quality plant-derived cannabinoid therapeutic products for specific medical conditions and diseases and to commercialise them through collaborations with pharmaceutical companies. Notably, the strategy has already resulted in GW Pharmerceutical’s production of the first cannabis plant-derived medicine ever approved by the FDA, Epidiolex®, a cannabidiol-based formulation for seizures associated with two forms of drug-resistant epilepsy syndromes.
In addition to its biopharmaceutical research and development business segment, Cannabinoid Biosciences also offers investment-related and professional financial services specifically to other cannabis businesses and investors in California and other jurisdictions where cannabis is legal.
Cannabinoid Biosciences, Inc. (“CBDZ”): Making CBD/Cannabis Investment More Accessible
As a result of the currently high barriers, there is a need for the provision of bargain cannabis investment deals for ordinary investors. Cannabinoid Biosciences (“CBDZ”) is currently meeting that need. Driven by the belief that cannabis should be an open investment opportunity for all, the company has proposed a stock offering of 5,000,000 shares available to anyone, accredited or non-accredited investors — and even to those who do not have a stock brokerage account!
At $10 per share, for as little as $100, you can become an owner of nine shares of the company, the minimum investment plan it offers, before it finally lists on an exchange. Hence, with the offering, you would be purchasing licensed cannabis businesses at less than $2 in market cap for every $1 of revenue generated, which is far below the industry average. As spelled out in its Reg A + filing, the company plans to use the expected $50 million crowdfunded funds to purchase 10 dispensaries with cultivation licenses in a multi-state rollup.
CBDZ’s plan is to list on a major Canadian or US-based exchange such as CSE, NYSE, or Nasdaq. After its public listing, compared to the current NASDAQ/NYSE listed pool of Cannabis companies, CBDZ can ultimately have as much as $54 million in revenue. Also, it can attain a robust profitability of $17 million. Most exciting is the prospect that the company’s valuation can be as high as $7.1 billion after the listing.